Myths and fallacies in permanent prostate brachytherapy

Medical Dosimetry

Volumn 28, Issue 3, 2003, Pages 155-165

  Butler, Wayne M ^a   Merrick, Gregory S ^b  

^a WHEELING HOSPITAL   (United States)

^b NONE

Author keywords

Complications; Dosimetry; Prostate brachytherapy; Survival

Indexed keywords

ADULT; AGED; ARTICLE; BEAM THERAPY; BIOPSY; BODY WEIGHT; BRACHYTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PENIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; SEXUAL FUNCTION; URETHRA;

EID: 0141892573     PISSN: 09583947     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-3947(03)00066-9     Document Type: Article

References (74)

1. Holm H.H., Juul J., Pederson J.F., et al. Transperineal 125-iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J. Urol. 130:1983;283-286.
2. Blasko J.C., Ragde H., Schumacher D., et al. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endocuriether. Hyperther. Oncol. 3:1987;131-139.
3. Carter H.B., Epstein J.I., Partin A.W. Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology. 53:1999;126-130.
4. Catalona W.J., Smith D. Five-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J. Urol. 152:1994;1837-1842.
5. Herold D.M., Hanlon A.L., Movsas B., et al. Age related prostate cancer metastases. Urology. 51:1998;985-990.
6. Catalona W.J., Smith D. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer Intermediate-term results . J. Urol. 160:1998;2428-2434.
7. Pound C.R., Partin A.W., Epstein J.I., et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy Patterns of recurrence and cancer control . Urol. Clin. North Am. 24:1997;395-406.
8. Han M., Partin A.W., Piantadosi S., et al. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J. Urol. 166:2001;416-419.
9. Blasko J.C., Grimm P.D., Sylvester J.E. Palladium-103 brachytherapy for prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 46:2000;839-850.
10. Merrick G.S., Butler W.M., Galbreath R.W., et al. 5-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 51:2001;41-48.
11. Merrick G.S., Butler W.M., Lief J.H., et al. Five-year biochemical outcome after prostate brachytherapy for hormone-naive men ≤ 62 years of age. Int. J. Radiat. Oncol. Biol. Phys. 50:2001;1253-1257.
12. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J. Clin. Oncol. 18:2000;1164-1172.
13. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer. Mol. Urol. 4:2000;171-175.
14. D'Amico A.V., Schultz D., Silver B., et al. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 49:2001;679-684.
15. Sebo T.J., Bock B.J., Cheville J.C., et al. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J. Urol. 163:2000;174-178.
16. Wills M.L., Sauvageot J., Partin A.W., et al. Ability of sextant biopsies to predict radical prostatectomy stage. Urology. 51:1998;759-764.
17. Grossfeld G.D., Chang J.J., Broering J.M., et al. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy Results from the cancer of the prostate strategic urologic research endeavor database . J. Urol. 165:2001;851-856.
18. Tigrani V.S., Bhargava V., Shinohara K., et al. Number of positive systematic sextant biopsies predicts surgical margin status at radical prostatectomy. Urology. 54:1999;689.
19. Gao X., Mohideen N., Flanigan R.C., et al. The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer Implications for treatment selection . J. Urol. 164:2000;1982-1986.
20. Merrick, G.S.; Butler, W.M.; Galbreath, R.W.; et al. The relationship between percent positive biopsies and biochemical outcome following permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland. Int. J. Radiat. Oncol. Biol. Phys. In press.
21. Stone N.N., Stock R.G., Parikh D., et al. Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate. J. Urol. 160:1998;1722-1726.
22. Vargas S.O., Jiroutek M., Welch W.R., et al. Perineural invasion in prostate need biopsy specimens. Am. J. Clin. Pathol. 111:1999;223-228.
23. de la Taille A., Rubin M.A., Bagiella E., et al. Can perineural invasion on prostate needle biopsy predict prostate specific antigen recurrence after radical prostatectomy? J. Urol. 162:1999;103-106.
24. Rubin M.A., Bassily N., Sanda M., et al. Relationship and significance of greatest percentage of tumor and perineural invasion on needle biopsy in prostatic adenocarcinoma. Am. J. Surg. Pathol. 24:2000;183-189.
25. Endrizzi J., Seay T. The relationship between early biochemical failure and perineural invasion in pathological T2 prostate cancer. BJU Int. 85:2000;696-698.
26. Egan A.J., Bostwick D.G. Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings Perineural invasion lacks significance on multivariate analysis . Am. J. Surg. Pathol. 21:1997;1496-1500.
27. Epstein J.I. The role of perineural invasion and other biopsy characteristics as prognostic markers for localized prostate cancer. Semin. Urol. Oncol. 16:1998;124-128.
28. O'Malley K.J., Pound C.R., Walsh P.C., et al. Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy. Urology. 59:2002;85-90.
29. Bonin S.R., Hanlon A.L., Lee W.R., et al. Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy. Cancer. 79:1997;75-80.
30. Grann A., Gaudin P.B., Raben A., et al. Pathologic features from prostate needle biopsy and prognosis after I-125 brachytherapy. Radiat. Oncol. Invest. 6:1998;170-174.
31. Merrick G.S., Butler W.M., Galbreath R.W., et al. Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy. Cancer J. Sci. Am. 7:2001;404-412.
32. Chan T.Y., Partin A.W., Walsh P.C., et al. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology. 56:2000;823-827.
33. Sakr W.A., Tefilli M.V., Grignon D.J., et al. Gleason score 7 prostate cancer A heterogeneous entity? Correlation with pathologic parameters and disease-free survival . Urology. 56:2000;730-734.
34. Han M., Snow P.B., Epstein J.I., et al. A neural network predicts progression for men with Gleason score 3+4 versus 4+3 tumors after radical prostatectomy. Urology. 56:2000;994-999.
35. Anderson P.R., Hanlon A.L., Horwitz E., et al. Outcome and predictive factors for patients with Gleason score 7 prostate carcinoma treated with three-dimensional conformal external beam radiation therapy. Cancer. 89:2000;2565-2569.
36. Merrick, G.S.; Butler, W.M.; Galbreath, R.W.; et al. Biochemical outcome for hormone naïve patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostate brachytherapy. Urology. In press.
37. Prestidge B.R., Bice W.S., Prete J.J., et al. A dose volume analysis of permanent transperineal prostatic brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 39:1997;238.
38. Badiozamani K.R., Wallner K., Sutlief S., et al. Anticipating prostatic volume changes due to prostate brachytherapy. Radiat. Oncol. Invest. 7:1999;360-364.
39. Merrick G.S., Butler W.M., Dorsey A.T., et al. The effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation. Tech. Urol. 7:2001;233-240.
40. Merrick, G.S.; Butler, W.M.; Wallner, K.E. et al. Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity. Urology 60:98-103; 2002.
41. Zippe C.D., Kedia A.W., Kedia K., et al. Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology. 52:1998;963-966.
42. Lepor H., Gregerman M., Crosby R., et al. Precise localization of the autonomic nerves from the pelvic plexus to the corpora cavernousa A detailed anatomical study of the adult male pelvis . J. Urol. 133:1985;207-212.
43. Zelefsky M.J., Wallner K.E., Ling C.C., et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J. Clin. Oncol. 17:1999;517-522.
44. DiBiase S.J., Wallner K., Tralins K., et al. Brachytherapy radiation doses to the neurovascular bundles. Int. J. Radiat. Oncol. Biol. Phys. 46:2000;1301-1307.
45. Merrick G.S., Butler W.M., Dorsey A.T., et al. A comparison of radiation dose to the neurovascular bundles in men with and without prostate brachytherapy-induced erectile dysfunction. Int. J. Radiat. Oncol. Biol. Phys. 48:2000;1069-1074.
46. Merrick G.S., Butler W.M., Lief J.H., et al. Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction. Urol. 53:1999;1112-1116.
47. Merrick G.S., Wallner K., Butler W.M., et al. A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy induced erectile dysfunction. Int. J. Radiat. Oncol. Biol. Phys. 50:2001;597-604.
48. Zeitlin S.I., Sherman J., Raboy A., et al. High dose combination radiotherapy for the treatment of localized prostate cancer. J. Urol. 160:1998;91-96.
49. Stock R.G., Stone N.N., Iannuzzi C. Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 35:1996;267-272.
50. Sharkey J., Chovnick S., Behar R., et al. Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate A preliminary report of 434 patients . Urology. 51:1998;796-803.
51. Litwin M.S., Lubeck D.P., Henning J.M., et al. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer Results of the CaPSURE database J. Urol. 159:1998;1988-1992.
52. Merrick, G.S.; Butler, W.M.; Galbreath, R.W.; et al. Erectile function after permanent prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 52:893-902; 2002.
53. Stock R.G., Kao J., Stone N.N. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J. Urol. 165:2001;436-439.
54. Zelefsky M.J., Wallner K.E., Ling C.C., et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early stage prostate cancer. J. Clin. Oncol. 17:1999;517-522.
55. Potters L., Torre T., Fearn P., et al. Potency after permanent prostate brachytherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 50:2001;1235-1242.
56. Blasko J.C., Ragde H., Grimm P.D. Transperineal ultrasound-guided implantation of the prostate Morbidity and complications . Scand. J. Urol. Nephrol. Suppl. 137:1991;113-118.
57. Talcott J.A., Clark J.C., Stark P., et al. Long-term treatment related complications of brachytherapy for early prostate cancer A survey of patients previously treated . J. Urol. 166:2001;494-499.
58. Wallner K., Roy J., Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;465-471.
59. Terk M.D., Stock R.G., Stone N.N. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J. Urol. 160:1998;1379-1382.
60. Merrick G.S., Butler W.M., Lief J.H., et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 47:2000;121-128.
61. Merrick G.S., Butler W.M., Galbreath R.W., et al. The relationship between the transition zone index of the prostate gland and urinary morbidity following brachytherapy. Urology. 57:2001;524-529.
62. Merrick G.S., Butler W.M., Tollenaar B.G., et al. The dosimetry of prostate brachytherapy-induced urethral strictures. Int. J. Radiat. Oncol. Biol. Phys. 52:2002;461-468.
63. Aggarwal S., Wallner K., True L.D., et al. Prostate brachytherapy in patients with prior evidence of prostatitis. Int. J. Radiat. Oncol. Biol. Phys. 45:1999;867-869.
64. Hughes, S.; Wallner, K.E.; Merrick, G.S.; et al. Pre-existing histologic evidence of prostatitis is unrelated to post-implant urinary morbidity. Int. J. Cancer (Radiat. Oncol. Invest.) 96(Suppl):79-82; 2001.
65. Wallner K., Lee H., Wasserman S., et al. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior TURP. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;565-569.
66. Stone N.N., Ratnow E.R., Stock R.G. Prior transurethral resection does not increase morbidity following real-time ultrasound-guided prostate seed implantation. Tech. Urol. 6:2000;123-127.
67. Potters L., Torre T., Ashley R., et al. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J. Clin. Oncol. 18:2000;1187-1192.
68. Merrick, G.S.; Butler, W.M.; Lief, J.H.; et al. Biochemical outcome for hormone naïve patients with high risk prostate cancer managed with permanent interstitial brachytherapy. Cancer J. Sci. Am. 8:322-7; 2002.
69. Partin A.W., Kaftan M.W., Subbing E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. JAMA. 277:1997;1445-1451.
70. Sohayda C., Kupelian P.A., Levin H.S., et al. Extent of extraprostatic extension in localized prostate cancer. Urol. 55:2000;382-386.
71. Theodorescu D., Frierson H.F., Sikes R.A. Molecular determination of surgical margins using fossa biopsies at radical prostatectomy. J. Urol. 161:1999;1442-1448.
72. Butler W.M., Merrick G.S., Lief J.H., et al. Comparison of seed loading approaches in prostate brachytherapy. Med. Phys. 27:2000;381-392.
73. Merrick G.S., Butler W.M. Modified uniform seed loading for prostate brachytherapy Rationale, design, and evaluation . Tech. Urol. 6:2000;78-84.
74. Merrick, G.S.; Butler, W.M.; Wallner, K.E.; et al. Extracapsular radiation dose distribution following permanent prostate brachytherapy. Amer. J. Clin. Oncol. In press.